Delivery of temperature sensitive items including proteins and kits will be paused on 6/19 for the Juneteenth holiday. For urgent orders please contact customer service.
C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulation factor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .
Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM .
D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation .
Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .
Canine Factor IX is a functional coagulation factor. Canine Factor IX shortens whole blood clotting time and activated partial thromboplastin time, and restores coagulation function. After intramuscular administration via rAAV vector in hemophilia B dogs, Canine Factor IX maintains a sustained circulating level for at least 1 year, partially corrects the hemophilia B phenotype in a dose-dependent manner, and its plasma expression persists for more than 17 months. Canine Factor IX is applicable to relevant research on hemophilia B .
Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research .
Cy3 Dextran (MW 20000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Cy3 Dextran (MW 10000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Boc-Gln-Gly-Arg-AMC is a fluorogenic substrate for kallikrein (PKa), coagulation factor XIIa (FXIIa) and coagulation factor XIa (FXIa). Boc-Gln-Gly-Arg-AMC enables fluorescence-based activity assays for PKa, FXIIa and FXIa .
Octocog alfa (ADVATE; BAY 81-8973; Kovaltry) is a standard half-length recombinant coagulation factorFVIII replacement therapy that also functions as a thrombin generation modulator. Octocog alfa regulates thrombin generation-related parameters in vitro and is used in studies related to severe hemophilia A .
Cy3 Dextran (MW 70000) is a fluorescent labeling reagent that conjugates the Cy3 (HY-D0822) fluorescent dye with Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. The maximum emission wavelength of Cy3 is approximately 562-570 nm. Dextran inhibits platelet aggregation and coagulation factors, and serves as a plasma volume expander .
Activated protein C is an anticoagulant targeting coagulation factors Va and VIIIa. Activated protein C demonstrates cytoprotective effects through binding to endothelial cell protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1), regulating gene expression, anti-inflammation, anti-apoptosis, and stabilizing endothelial barriers. Activated protein C is promising for research of diseases such as severe sepsis and ischemic stroke .
Turoctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa pegol can be used for researching haemophilia A .
FXIa/Plasma kallikrein-IN-1 is an inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein with Ki values of 187.70 nM and 151.6 nM, respectively. FXIa/Plasma kallikrein-IN-1 can be used in the research of thromboembolic diseases .
Boc-Glu(OBzl)-Ala-Arg-AMC is a fluorogenic substrate for coagulation factor XIa and trypsin. The cleavage of the amide bond between arginine and the methylcoumarin amide group releases fluorescent 7-Amino-4-methylcoumarin (HY-D0027) .
NAPAP is a selective direct thrombin inhibitor. NAPAP rapidly binds to thrombin and inhibits its activity, and reduces LPS (HY-D1056)-induced brain inflammation and coagulation factor expression in vivo. NAPAP can be used in studies related to coagulation and neuroinflammation .
Cy3 Dextran (MW 3000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Dextran-CY5.5 is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting humancoagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), used in the research of coronary heart disease (CHD).
E-76 is a peptide with anticoagulant activity. E-76 inhibits blood coagulation by specifically binding to exogenous coagulation factor VIIa (FVIIa). E-76 can be used to study blood coagulation-related diseases .
Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia .
Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
Cy3 Dextran (MW 40000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Cy3 Dextran (MW 100000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Dextran-CY5.5 (MW 10000) is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
Dextran-CY5.5 (MW 40000) is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
Difethialone (Standard) is the analytical standard of Difethialone. This product is intended for research and analytical applications. Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B .
EMD 495235 is a potent and orally active coagulation factor Xa inhibitor with an IC50 of 5.5 nM and a Ki of 6.8 nM. EMD 495235 shows anticoagulant activities .
Bovine Factor X is a bovine derived coagulation factor. Canine Factor X can be converted to activated Factor Xa, which can can convert prothrombin to thrombin .
Amrecibart is an anti-coagulation factor11human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Anivamersen is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
Asundexian-d3 (BAY-2433334-d3) is the deuterium labeled Asundexian (HY-137431). Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM .
DEAE-dex-Cy5 is a fluorescent labeling reagent that combines Cy5 (HY-D0821) fluorescent dye, Dextran (dex) and Diethylaminoethyl (DEAE). Cy5 is a Cyanine dye (with a long wavelength about 662nm) that can be used for molecular labeling and microscopy imaging. Dex has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
(1R,2R,4R)-Edoxaban is an oxalamide derivative. (1R,2R,4R)-Edoxaban is an activated coagulation factor X (Factor Xa) inhibitor. (1R,2R,4R)-Edoxaban can be used in the study of thrombosis .
Cy3 Dextran (MW 500000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Cy3 Dextran (MW 5000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Cy3 Dextran (MW 2000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Difethialone-d4 (Baraki-d4; LM 2219-d4) is the deuterium labeled Difethialone (HY-113958). Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
Tecarfarin (ATI-5923) sodium is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin sodium blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin sodium prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin sodium is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
Tecarfarin (ATI-5923) (Standard) is the analytical standard of Tecarfarin. This product is intended for research and analytical applications. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
Tecarfarin- 13C,d3 (ATI-5923- 13C,d3) is 13C labeled Tecarfarin. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
BMS-962212 hydrochloride is a selective coagulation factor XIa inhibitor and acute antithrombotic agent. BMS-962212 hydrochloride can be used in the research of thrombosis .
FXa-IN-3 (compound 1a) is a potent coagulation factor Xa (FXa) inhibitor with a Ki of 43 nM. FXa-IN-3 can be used in the research of thromboembolic diseases .
Rabbit Factor X is a rabbit derived coagulation factor. Canine Factor X can be converted to activated Factor Xa, which can can convert prothrombin to thrombin .
Vitamin K-d7 is the deuterium labeled Vitamin K (HY-B2172). Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.
L-Guluronic acid is a coagulation factor X inhibitor. L-Guluronic acid can replace L-Iduronic acid (HY-135197) in the anticoagulant pentasaccharide of heparin-like substances, while retaining the inhibitory activity against factor Xa. L-Guluronic acid can be used in the research of diseases with coagulation disorders such as deep vein thrombosis and pulmonary embolism .
Difethialone-d4-1 (LM-2219-d4-1) is the deuterium labeled Difethialone (HY-113958). Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
Cy3 Dextran (MW 20000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Cy3 Dextran (MW 10000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Cy3 Dextran (MW 70000) is a fluorescent labeling reagent that conjugates the Cy3 (HY-D0822) fluorescent dye with Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. The maximum emission wavelength of Cy3 is approximately 562-570 nm. Dextran inhibits platelet aggregation and coagulation factors, and serves as a plasma volume expander .
Cy3 Dextran (MW 3000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Dextran-CY5.5 is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
Cy3 Dextran (MW 40000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Cy3 Dextran (MW 100000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Dextran-CY5.5 (MW 10000) is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
Dextran-CY5.5 (MW 40000) is a CY5.5 (HY-D0924) labeled Dextran (HY-112624) conjugate. CY5.5 is a Cyanine dye (The excitation wavelength is usually 673 nm and the emission wavelength is 707 nm) that can be used for the labeling of proteins, antibodies and small molecular compounds. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
DEAE-dex-Cy5 is a fluorescent labeling reagent that combines Cy5 (HY-D0821) fluorescent dye, Dextran (dex) and Diethylaminoethyl (DEAE). Cy5 is a Cyanine dye (with a long wavelength about 662nm) that can be used for molecular labeling and microscopy imaging. Dex has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander .
Cy3 Dextran (MW 500000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Cy3 Dextran (MW 5000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
Cy3 Dextran (MW 2000) is a fluorescent labeling reagent that combines Cy3 (HY-D0822) fluorescent dye and Dextran (HY-112624). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Dextran has an inhibitory effect on thrombocyte aggregation and coagulation factors and is used as a plasma volume expander (Ex/Em = 550/570 nm) .
C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulation factor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .
D-Pro-Phe-Arg-Chloromethylketone, a inhibitor of coagulation factor XII and plasma kallikrein, plays an important role in thrombosis and inflammation .
Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .
Boc-Gln-Gly-Arg-AMC is a fluorogenic substrate for kallikrein (PKa), coagulation factor XIIa (FXIIa) and coagulation factor XIa (FXIa). Boc-Gln-Gly-Arg-AMC enables fluorescence-based activity assays for PKa, FXIIa and FXIa .
Boc-Glu(OBzl)-Ala-Arg-AMC is a fluorogenic substrate for coagulation factor XIa and trypsin. The cleavage of the amide bond between arginine and the methylcoumarin amide group releases fluorescent 7-Amino-4-methylcoumarin (HY-D0027) .
Thrombin Receptor Activator for Peptide 5 (TRAP-5) is also called Coagulation Factor II Receptor (1-5) or Proteinase Activated Receptor 1 (1-5), used in the research of coronary heart disease (CHD).
E-76 is a peptide with anticoagulant activity. E-76 inhibits blood coagulation by specifically binding to exogenous coagulation factor VIIa (FVIIa). E-76 can be used to study blood coagulation-related diseases .
MCE Blue Agarose 6FF can be used for the purification of biological macromolecules such as albumin, interferons, nucleotide-dependent enzymes (e.g., kinases, dehydrogenases), α2-macroglobulin, and coagulation factors.
MCE Heparin Agarose 6FF is suitable for the separation and purification of heparin-binding biomolecules, including antithrombin III, coagulation factors, other plasma proteins, DNA-binding proteins, lipoproteins, protein synthesis factors, nucleic acid-related enzymes, and steroid receptors.
Turoctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa pegol can be used for researching haemophilia A .
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting humancoagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .
Zemocimig is an anti-coagulation factor F9 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Bemiltenase alfa is a hemostatic agent targeting coagulation factor X (FX). Bemiltenase alfa activates FX and promotes the conversion of prothrombin to thrombin, and thrombin can further transform fibrinogen into fibrin, forming a stable blood clot, thus exerting hemostatic activity. Bemiltenase alfa is promising for research of bleeding symptoms with hemophilia .
Nonacog gamma is a coagulation factor IX (FIX) supplement. Nonacog gamma activates coagulation factor X (FX), promotes the generation of thrombin, and then converts fibrinogen into fibrin, forming a stable blood clot to exert hemostatic activity. Nonacog gamma is promising for research of hemophilia B .
Amrecibart is an anti-coagulation factor11human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003) .
Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.
L-Guluronic acid is a coagulation factor X inhibitor. L-Guluronic acid can replace L-Iduronic acid (HY-135197) in the anticoagulant pentasaccharide of heparin-like substances, while retaining the inhibitory activity against factor Xa. L-Guluronic acid can be used in the research of diseases with coagulation disorders such as deep vein thrombosis and pulmonary embolism .
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. Coagulation Factor XII/F12 Protein, Pig (His) is the recombinant pig-derived Coagulation Factor XII/F12 protein, expressed by E. coli , with N-6*His labeled tag.
Coagulation factor XI (F11) occupies a central position in the middle phase of the intrinsic pathway of blood coagulation, where it assumes the key role of activating factor IX. This complex process plays a key role in the chain of events that lead to the formation of a blood clot. Coagulation Factor XI/F11 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation Factor XI/F11 protein, expressed by HEK293 , with C-His labeled tag.
Coagulation Factor II/F2, also known as thrombin, functions as a pivotal serine protease. Its enzymatic action involves cleaving bonds after Arg and Lys residues, facilitating the conversion of fibrinogen to fibrin. Thrombin additionally activates key factors like V, VII, VIII, XIII, and, in conjunction with thrombomodulin, protein C. Beyond blood homeostasis, thrombin plays a role in inflammation and the complex dynamics of wound healing. Coagulation Factor II/F2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor II/F2 protein, expressed by HEK293 , with C-His labeled tag.
The factor II/F2 protein (also known as thrombin) plays a key role in blood homeostasis, inflammation, and wound healing. As a multifunctional enzyme, it catalyzes the conversion of fibrinogen into fibrin to form the coagulation network. Coagulation Factor II/F2 Protein, Rat (HEK293, His) is the recombinant rat-derived Coagulation Factor II/F2 protein, expressed by HEK293 , with C-His labeled tag.
Coagulation factor XII (F12) is a serum glycoprotein that plays multiple roles in initiating blood coagulation, fibrinolysis, and the production of bradykinin and angiotensin. It is involved in these complex processes, including cleavage of prekallikrein to form kallikrein, which subsequently cleaves factor XII initially to α-factor XIIa and then, after trypsin cleavage, to β-factor XIIa. Coagulation Factor XII/F12 Protein, Pig (P. pastoris, His) is the recombinant pig-derived F12/Coagulation Factor XII, Pig, expressed by P. pastoris , with N-6*His labeled tag.
Factor IX (F9) is a vitamin K-dependent plasma protein that plays a critical role in the intrinsic pathway of coagulation. Factor IX coordinates the conversion of factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa. Coagulation factor IX/F9 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor IX/F9 protein, expressed by HEK293 , with C-6*His labeled tag.
Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation factor VII/F7 Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor VII/F7, expressed by HEK293, with C-His labeled tag.
Coagulation Factor IX/F9 Protein, a vital vitamin K-dependent plasma protein, is pivotal in the intrinsic blood coagulation pathway. Its role includes converting factor X into its active form, a process facilitated by Ca(2+) ions, phospholipids, and factor VIIIa. Coagulation Factor IX/F9 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor IX/F9 protein, expressed by HEK293 , with C-His labeled tag.
Coagulation factor XI (F11) occupies a central position in the middle phase of the intrinsic pathway of blood coagulation, where it assumes the key role of activating factor IX. This complex process plays a key role in the chain of events that lead to the formation of a blood clot. Coagulation Factor XI/F11 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Coagulation Factor XI/F11 protein, expressed by HEK293 , with C-His labeled tag.
Coagulation factor XIII B/F13B Proteinas, the B chain of factor XIII, lacks catalytic activity but stabilizes A subunits and regulates thrombin-initiated transglutaminase formation. Functioning as a tetramer with two A chains (F13A1) and two B chains (F13B), it structurally supports the factor XIII complex, emphasizing its regulatory role in blood coagulation, particularly in transglutaminase activation by thrombin. Coagulation factor XIII B/F13B Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor XIII B/F13B protein, expressed by HEK293 , with C-His labeled tag.
Coagulation Factor VII (F7) protein lacks crucial conserved residue(s) needed for propagating feature annotation. Coagulation Factor VII/F7 Protein, Mouse (CHO, His) is the recombinant mouse-derived Coagulation Factor VII/F7 protein, expressed by CHO , with C-His labeled tag.
Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation factor VII/F7 Protein, Human (His-SUMO) is the recombinant human-derived Coagulation factor VII/F7 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
Coagulation Factor X/F10 Protein, a crucial vitamin K-dependent glycoprotein, is central to blood clotting. It produces Factor Xa, essential for converting prothrombin to thrombin, a process facilitated by factor Va, calcium, and phospholipid in the intricate cascade of blood coagulation. Coagulation Factor X/F10 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor X/F10 protein, expressed by HEK293 , with C-6*His labeled tag.
Coagulation factor VII (F7) initiates the extrinsic pathway of blood coagulation. As a circulating zymogen, F7 is activated to F7a through proteolysis induced by factor Xa, factor XIIa, factor IXa, or thrombin. In the presence of tissue factor and calcium ions, F7a catalyzes limited proteolysis of factor X, converting it to factor Xa. F7a can also convert factor IX to factor IXa, emphasizing its pivotal role in coagulation cascades. Coagulation Factor VII/F7 Protein, Human (HEK293, His, solution) is the recombinant human-derived Coagulation Factor VII/F7 protein, expressed by HEK293 , with C-His labeled tag.
Coagulation factor III/F3 Protein, Human (HEK293, His) is a recombinant human CD142 expressed in HEK 293 cells with a His tag at the C-terminus. Coagulation Factor III/CD142 Protein is a principal regulator of oncogenic neoangiogenesis and controls therefore the cancerous process.
Factor X (F10) is a vitamin K-dependent glycoprotein that plays a key role in the blood coagulation process as factor Xa. Factor Xa, along with factor Va, calcium, and phospholipids, coordinates the conversion of prothrombin to thrombin, a key step in the coagulation cascade. Coagulation Factor X/F10 Protein, Human (HEK293, Fc) is the recombinant human-derived Coagulation Factor X/F10 protein, expressed by HEK293 , with C-hFc labeled tag.
Coagulation factor III/F3 Protein, Human (HEK293, Fc) is a recombinant human CD142 expressed in HEK 293 cells with a Fc tag at the C-terminus. Coagulation Factor III/CD142 Protein is a principal regulator of oncogenic neoangiogenesis and controls therefore the cancerous process.
Coagulation Factor III (F3), or Tissue Factor (TF), initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex critically activates factors IX or X through limited proteolysis, initiating the coagulation cascade on the cell surface. F3's interaction with HSPE, inhibited by heparin, promotes the generation of activated factor X, emphasizing its central role in regulating hemostatic processes. Coagulation Factor III/F3 Protein, Canine (HEK293, His) is the recombinant canine-derived Coagulation Factor III/F3 protein, expressed by HEK293 , with C-His labeled tag.
rHucoagulationfactorxiII A chain/F13A, his; coagulationfactorxiII A Chain; coagulationfactorxiIIa; protein-Glutamine Gamma-Glutamyltransferase A Chain; Transglutaminase A Chain; F13A1; F13A
Coagulation factor XIII A chain is the A chain of factor XIII. As a coagulation factor, Factor XIII A chain alters clot stabilization and bleeding. Factor XIII A chain regulates multiple aspects of wound healing: stabilizes fibrin clots and extracellular matrix, modulates monocyte functions, promote angiogenesis, and upregulates proangiogenic early growth response transcription factor 1. Coagulation factor XIII A/F13A Protein, Human (HEK293, His) is the recombinant human-derived Coagulation factor XIII A/F13A protein, expressed by HEK293 , with C-6*His labeled tag.
Tissue factor (TF) initiates blood coagulation by forming a complex with circulating factor VII or VIIa, thus forming the [TF:VIIa] complex. This complex is capable of specific limited proteolysis of factors IX or X and plays a key role in normal hemostasis by initiating the coagulation protease cascade. Tissue Factor Protein, Mouse (HEK293, His) is the recombinant mouse-derived Tissue Factor protein, expressed by HEK293 , with C-6*His labeled tag.
F3 Protein, a cell surface receptor, plays a significant role in regulating blood coagulation and promoting cell adhesion. Dysregulation of F3 Protein has been associated with various disorders, including thrombosis and cancer. Targeting F3 Protein may offer potential therapeutic interventions in these conditions by inhibiting blood clot formation and preventing tumor cell adhesion and metastasis. Tissue Factor Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Tissue Factor protein, expressed by HEK293 , with C-His labeled tag.
Tissue Factor Protein plays a critical role in blood coagulation.It binds to coagulation factors, activating clotting cascades.Tissue Factor Protein interacts with cells, promoting thrombosis and inflammation.Understanding its functions can aid in developing treatments for blood disorders and cardiovascular diseases.Tissue Factor Protein, Rat (HEK293, His) is the recombinant rat-derived Tissue Factor protein, expressed by HEK293 , with C-His labeled tag.
Tissue Factor Protein initiates blood coagulation by binding to coagulation factors. It activates clotting cascades and interacts with cells to promote thrombosis and inflammation. Understanding Tissue Factor Protein's functions is crucial for developing treatments for cardiovascular diseases and blood disorders. Tissue Factor Protein, Rabbit (HEK293, His) is the recombinant Rabbit-derived Tissue Factor protein, expressed by HEK293 , with C-His labeled tag.
Factor XIV/PROC protein (or protein C) is an important vitamin K-dependent serine protease that regulates blood clotting.Protein C plays a crucial role in inactivating factors Va and VIIIa and regulating the coagulation cascade in the presence of calcium ions and phospholipids.Coagulation Factor XIV/PROC Protein, Mouse (HEK293, His) is the recombinant mouse-derived Coagulation Factor XIV/PROC protein, expressed by HEK293 , with C-His labeled tag.
Coagulation Factor XIV/PROC is a vital vitamin K-dependent serine protease regulating blood coagulation. Active Protein C inactivates factors Va and VIIIa in the presence of calcium ions and phospholipids, maintaining the intricate balance of coagulation pathways. Its protective effect on endothelial cell barrier function underscores a broader impact on vascular integrity. Coagulation Factor XIV/PROC Protein, Human (HEK293, His) is the recombinant human-derived Coagulation Factor XIV/PROC protein, expressed by HEK293 , with C-His labeled tag. The total length of Coagulation Factor XIV/PROC Protein, Human (HEK293, His) is 443 a.a., with molecular weight of 56-64 & 45 kDa, respectively.
rHuDiscoidin, CUB and LCCL domain-containing protein 2/ DCBLD2, his; Discoidin; CUB and LCCL domain-containing protein 2; DCBLD2; CUB; LCCL and coagulationfactor V/VIII-homology domains protein 1; Endothelial and smooth muscle cell-derived neuropilin-like protein; DCBLD2; CLCP1; ESDN;
DCBLD2 Protein is a novel platelet membrane receptor that recruits TRAF6 through EGFR phosphorylation and stimulates AKT to promote tumorigenesis. The DCBLD2 Protein has multiple functions during development as well as in vascular and tumor biology, such as influencing cell proliferation and tumorigenesis. DCBLD2 Protein, Human (HEK293, His) is the recombinant human-derived DCBLD2 protein, expressed by HEK293 , with C-6*His labeled tag.
Asundexian-d3 (BAY-2433334-d3) is the deuterium labeled Asundexian (HY-137431). Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM .
Difethialone-d4 (Baraki-d4; LM 2219-d4) is the deuterium labeled Difethialone (HY-113958). Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
Tecarfarin- 13C,d3 (ATI-5923- 13C,d3) is 13C labeled Tecarfarin. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
Vitamin K-d7 is the deuterium labeled Vitamin K (HY-B2172). Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.
Difethialone-d4-1 (LM-2219-d4-1) is the deuterium labeled Difethialone (HY-113958). Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
C12-200 is a type of ionizable cationic lipid and helper lipid commonly used for mRNA delivery. In the hemophilia B mouse model, mRNA encoding human erythropoietin (EPO) and coagulation factor IX (FIX) can be successfully delivered and expressed using C12-200. C12-200 is utilized in research related to hemophilia B .
Anivamersen is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
Inquiry Online
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
